

**ASSESSMENT OF COMPLEX EFFICIENCY OF THE THERAPY BY ACTOVEGIN
IN THE TREATMENT OF COMPLICATIONS OF DIABETES MELLITUS TYPE 2**

L.A. Kuzina, N.S. Kayshibayev, A.V. Emelyanov, A.S. Tlegenov
*Scientific and Practical Center, Institut of Neurology named by Smagul
Kayshibayev and Medical Center SunCar, Almaty, Kazakhstan*

Objective: The study involved 30 patients with a diagnosis of diabetes type 2 duration 1,5-10 years, with clinical manifestations of encephalopathy, retinopathy, distal sensory polyneuropathy.

Methods: Integrated clinical and neurological research included analysis of the complaints of patients, rate of neuropathy symptoms on the scale NSS (Neuropathy Symptom Score), the neurological deficit on the scale NDS (Neuropathy Disability Score), neurophysiological examination of the lower limbs nerves, assessment of cognitive function on the MMSE (Mini Mental State Examination), test of memorizing 10-words, clock-drawing test, vascular assessment of the ocular fundus by retinoscopy. After a survey was carried out therapy by Actovegin on scheme - 1200 mg intravenous injections for ten days, then 600 mg/day for 3 months per os. The control visits was 6 and 12 weeks after therapy.

Results: Increase on MMSE scale on 3.3, the clock-drawing test on 1.2. According to test of memorizing 10-words – a uniform gain volume of remembered material, as after the first presentation, and it is deferred. On the NSS scale reduction by 4.5, on NDS 3.3. Increase the average value of conduction velocity on lower limbs nerves at 4.0 m/s, the amplitude of sensual response at 0.4 μ V. The retinoscopy registered the improvement of vessels as reducing spasm and tortuosity of the arteries and plethora by veins.

Conclusions: Complex efficiency of 12- weeks' therapy by Actovegin in the treatment of complications of diabetes type 2 is shown.